Literature DB >> 11899892

Molecular incompatibilities in hemostasis between swine and men--impact on xenografting.

J Schulte am Esch1, X Rogiers, S C Robson.   

Abstract

The rejection of xenografts is associated with vascular-based inflammation, thrombocytopenia and the consumption of coagulation factors that may evolve into disseminated intravascular coagulation. Natural regulators of coagulation in porcine xenografts have abnormal physiological interaction with human effectors. We have demonstrated the enhanced potential of porcine von Willebrand factor to associate with human platelet GPlb to be dependent upon the isolated AI domain of von Willebrand factor. The inability of porcine tissue factor pathway inhibitor (TFPI) to adequately neutralize human factor Xa (FXa), the aberrant activation of both human prothrombin and FXa by porcine EC and the failure of the porcine natural anticoagulant, thrombomodulin to bind human thrombin and hence activate human protein C may all be pathogenetic in the DIC following xenograft rejection. In this brief review, molecular incompatibilities of contributors in the physiologically fine tuned system of hemostasis are summarized and brought in context with the disordered thromboregulation, that seems to be invariably associated with delayed xenograft rejection. Possible therapeutic interventions are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11899892

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  10 in total

Review 1.  Antibody-mediated xenograft injury: mechanisms and protective strategies.

Authors:  Richard N Pierson
Journal:  Transpl Immunol       Date:  2009-04-17       Impact factor: 1.708

2.  Expression of human CD46 modulates inflammation associated with GalTKO lung xenograft injury.

Authors:  L Burdorf; T Stoddard; T Zhang; E Rybak; A Riner; C Avon; A Laaris; X Cheng; E Sievert; G Braileanu; A Newton; C J Phelps; D Ayares; A M Azimzadeh; R N Pierson
Journal:  Am J Transplant       Date:  2014-04-02       Impact factor: 8.086

Review 3.  Clinical lung xenotransplantation--what donor genetic modifications may be necessary?

Authors:  David K C Cooper; Burcin Ekser; Christopher Burlak; Mohamed Ezzelarab; Hidetaka Hara; Leela Paris; A Joseph Tector; Carol Phelps; Agnes M Azimzadeh; David Ayares; Simon C Robson; Richard N Pierson
Journal:  Xenotransplantation       Date:  2012 May-Jun       Impact factor: 3.907

Review 4.  Overcoming the barriers to xenotransplantation: prospects for the future.

Authors:  Burcin Ekser; David K C Cooper
Journal:  Expert Rev Clin Immunol       Date:  2010-03       Impact factor: 4.473

5.  Expression of tissue factor and initiation of clotting by human platelets and monocytes after incubation with porcine endothelial cells.

Authors:  Chih Che Lin; Daxin Chen; John H McVey; David K C Cooper; Anthony Dorling
Journal:  Transplantation       Date:  2008-09-15       Impact factor: 4.939

Review 6.  Current status of xenotransplantation and prospects for clinical application.

Authors:  Richard N Pierson; Anthony Dorling; David Ayares; Michael A Rees; Jörg D Seebach; Jay A Fishman; Bernhard J Hering; David K C Cooper
Journal:  Xenotransplantation       Date:  2009 Sep-Oct       Impact factor: 3.907

7.  Current status of xenotransplantation.

Authors:  Richard N Pierson
Journal:  JAMA       Date:  2009-03-04       Impact factor: 56.272

8.  Regulation of human platelet aggregation by genetically modified pig endothelial cells and thrombin inhibition.

Authors:  Hayato Iwase; Burcin Ekser; Hidetaka Hara; Carol Phelps; David Ayares; David K C Cooper; Mohamed B Ezzelarab
Journal:  Xenotransplantation       Date:  2013-11-05       Impact factor: 3.907

9.  Clinical xenotransplantation of organs: why aren't we there yet?

Authors:  Muhammad M Mohiuddin
Journal:  PLoS Med       Date:  2007-03-27       Impact factor: 11.069

10.  Immunodeficient mice are better for modeling the transfusion of human blood components than wild-type mice.

Authors:  Sophia A Blessinger; Johnson Q Tran; Rachael P Jackman; Renata Gilfanova; Jacqueline Rittenhouse; Alan G Gutierrez; John W Heitman; Kelsey Hazegh; Tamir Kanias; Marcus O Muench
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.